Abstract: Treating colorectal cancer in a stage IV uses a systemic chemotherapy, either a FOLFOX regimen or a FOLFIRI regimen. However, a method of predicting which of the regimens is effective to an individual patient would be advantageous. Provided is a biomarker that indicates which of the regimens, the FOLFOX regimen or the FOLFIRI regimen, is advantageous to select for a patient having colorectal cancer. The biomarker is characterized by being a gain in the copy number of at least one region on human chromosomes among 7p15.3, 7q34, 8q24.1, 8q24.2, 8q24.1-q24.2, 9q34.3, 13q12.2, 13q14.11, 13q22.1, 13q32.2-q32.3, 13q34, 20q12, 20q13.13, 20q13.2, and 20q13.3. Using such a biomarker enables to determine which, the FOLFOX regimen or the FOLFIRI regimen, is more advantageously selected.

Abstract: The purpose of the present invention is to provide a heat-sealing device capable of preventing problems associated with cap sealing performance and/or sensation of the cap being open due to an inappropriate cap temperature.

Abstract: The purpose of the present invention is to provide a detection device that detects the occurrence of an event (so-called “double capping”) in which two caps are disposed on one container. To that end, the detection device (10, 10A) of the present invention has two types of sensors provided on a production line (100) for a commercial product in which an opening (1A) of a container (1) is sealed with a cap (2), said sensors being a proximity sensor (3) along a path where the container (1) moves and a sensor (4: for example, a transmission sensor) equipped with a transmitter (4A), which is inside the same path, and a receiver (4B). An area detected by the sensors (3, 4) is an area where the cap (2) is not present in a normal state (a state in which double capping has not occurred), but where a subsequent cap (2-1) is present if two caps (2) in a row have been attached to one container (1).

Abstract: The invention relates to methods, composition and uses for the of treatment of cancer selected from the group consisting of HCC, RCC, NSCLC, ovarian cancer, CCA, PTC and FTC in a subject, which comprise administering an HDAC inhibitor in combination with a compound inhibiting the VEGF/VEGFR interaction, wherein said subject is characterized in having a platelet count of about 140000 platelets/?l or higher.

Abstract: Treating colorectal cancer in a stage IV uses a systemic chemotherapy, either a FOLFOX regimen or a FOLFIRI regimen. However, a method of predicting which of the regimens is effective to an individual patient has not been available. Provided is a biomarker that indicates which of the regimens, the FOLFOX regimen or the FOLFIRI regimen, is advantageous to select for a patient having colorectal cancer. The biomarker is characterized by being a gain in the copy number of at least one region on human chromosomes among 7p15.3, 7q34, 8q24.1, 8q24.2, 8q24.1-q24.2, 9q34.3, 13q12.2, 13q14.11, 13q22.1, 13q32.2-q32.3, 13q34, 20q12, 20q13.13, 20q13.2, and 20q13.3. Using such a biomarker enables to determine which, the FOLFOX regimen or the FOLFIRI regimen, is more advantageously selected.

Abstract: The present invention provides a novel dinuclear platinum(II) complex compound that can bind to DNA by a mode different from that of cisplatin-type drugs, a method of producing this compound and an anticancer agent comprising this compound as an effective component. This compound is a tetrazolato-bridged platinum complex compound represented by the following formula (I), wherein A is optionally substituted tetrazolato, B is an inorganic or organic anion, and m and n are integers determined in accordance with the charge number of the platinum complex ion and the charge number of the anion.

Abstract: The present invention provides a novel dinuclear platinum(II) complex compound that can bind to DNA by a mode different from that of cisplatin-type drugs, a method of producing this compound and an anticancer agent comprising this compound as an effective component. This compound is a tetrazolato-bridged platinum complex compound represented by the following formula (I), wherein A is optionally substituted tetrazolato, B is an inorganic or organic anion, and m and n are integers determined in accordance with the charge number of the platinum complex ion and the charge number of the anion.

Abstract: A kefir-like fermented milk is produced from a raw material, which contains lactose and at least one sugar, by subjecting the lactose to lactic acid fermentation with a lactic acid bacterium and the sugar to alcoholic fermentation with a yeast. The alcoholic fermentation is controlled, for example, by conducting same with a lactose non-fermenting and galactose non-fermenting yeast until all assimilable sugar sources are substantially eliminated. A gelatinous kefir-like fermented milk is also produced by controlling the alcoholic fermentation to start after addition of a gelling agent.